Participation in clinical trials and long-term outcomes in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The objective of this study was to determine whether participation in clinical trials affects long-term outcomes in Alzheimer's disease (AD). Participation in clinical trials for persons with dementia is often justified on the grounds that patients benefit from the medical oversight typical of trials, even when experimental agents do not demonstrate short-term benefits. This claim has not been rigorously assessed. Of 215 community-resident subjects enrolled in a prospective study of outcomes in AD, 101 participated in randomized clinical trials (RCTs) during the first 2 years of follow-up. These subjects were compared with subjects who met eligibility requirements for RCTs but did not participate (N = 57) and with subjects who were ineligible (N = 57), over a total of 3.5 years of follow-up. Survival analyses assessed risk of death, nursing home placement, and incident functional deficit end points, adjusting for baseline differences. Subjects who participated in RCTs were younger and more highly educated. Mortality, risk of hospitalization, number of medical examinations conducted by study physicians, and onset of severe functional deficit did not differ between the groups, but risk of nursing home admission was significantly lower among RCT participants compared with eligible nonparticipants and ineligible subjects (16.8% versus 36.8% and 31.6%, respectively [p = 0.01]). The difference in risk of nursing home placement may represent a long-term, drug-related benefit to patients, a selection effect (caregivers of patients who participate in RCTs differ from caregivers of patients who do not), or a positive effect on caregivers (greater contact with a medical service may be associated with better care-giving outcomes). Further research is required to assess these effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538
Bayes Estimates for the Linear Model
Lindley, D. V., & Smith, A. F. M. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00885.x · Cited by 2,025
Cited by
Alberts, M. J., Latchaw, R. E., Selman, W. R., Shephard, T., Hadley, M. N., Brass, L. M., Koroshetz, W., Marler, J. R., Booss, J., Zorowitz, R. D., et al. (2005) · Stroke · doi:10.1161/01.str.0000170622.07210.b4 · Cited by 585
Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based Recommendations
Cummings, J. L. (2003) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200303000-00004 · Cited by 202
Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease
Doody, R. S., Dunn, J. K., Clark, C. M., Farlow, M., Foster, N. L., Liao, T., Gonzales, N., Lai, E., & Massman, P. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051272 · Cited by 118
Miller, M. D., Crotty, M., Whitehead, C., Bannerman, E., & Daniels, L. A. (2006) · Clinical Rehabilitation · doi:10.1191/0269215506cr942oa · Cited by 92
The Relationship Between Donepezil and Behavioral Disturbances in Patients With Alzheimer's Disease
Cummings, J. L., Donohue, J. A., & Brooks, R. L. (2000) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200005000-00008 · Cited by 71
Metadata
- Authors
- Albert, S. M., Sano, M., Marder, K., Jacobs, D. M., Brandt, J., Albert, M., & Stern, Y.
- Venue
- Neurology
- Published
- 1997-07
- Volume
- 49
- Issue
- 1
- Pages
- 38-43
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1990508123
- Cited by
- 61
- References
- 2
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.